Oct 29, 2026 earnings call — Early-phase expansion and margin progress
Reported revenue of $691.5 million and adjusted EBITDA of $58 million for Q3.
Revenue $0.7B (est $0.7B) · EPS $0.28 (est $0.22)
Key quotes
"We're expanding our reach and generating more demand with the value of our pipeline increasing both sequentially and year-over-year."
"Across the global network, the transaction means that Fortrea now has more than 570 beds, adding to the scale and speed of our integrated early phase offering."
"In addition to the cancellations and contract amendments that occurred during the quarter, we also recorded a cumulative adjustment to backlog of $558 million."
Analyst Q&A 11
Why Q4 guide is lower and TSA
Q (Elizabeth Anderson · Evercore): She asked why the Q4 EBITDA guide was lower than expected and what factors drove it. She also asked how the Worldwide acquisition works with the TSA and when Fortrea starts supporting those clients.
A: Management said Q4 revenue should slow a bit because there are fewer working days in Q4 versus Q3. They also said they will step up some IT OpEx, and that a TSA covers HR, IT and finance support. They noted the commercial conversion from the acquired business is starting but will take time.
"We do expect a little bit of a sequential slowdown in revenue, and that's really just a function of the number of working days that are in Q4 versus Q3." — Jason Knoblauch (CFO)
Why backlog was adjusted and scope
Q (Eric Coldwell · Baird): He asked why the backlog adjustment was larger and broader than previously indicated. He wanted to know how much of the adjustment was inactive trials and whether this affects near-term or longer-term revenue.
A: They completed the assessment in Q3 to better represent remaining life revenue on contracts. The adjustment reflects both inactive-study dynamics and parts of the portfolio they expect not to deliver. They said this does not change variables used for revenue recognition or near- and medium-term revenue models and that the backlog represents many years of revenue.
"It is a mix of both inactive study dynamics as well as what we internally will call not to deliver dynamics within parts of the portfolio as well." — Jason Knoblauch (CFO)
Drivers of gross margin and burn rate
Q (Luke Sergott · Barclays): He asked what drove the gross margin improvement after backing out pass-throughs and whether past initiatives are working. He also asked if the Q4 guide implies about an 8.5% burn rate and if that is a good starting point for 2027.
A: They said margin improvement comes as contracts and backlog convert to higher-economics work and from operations efficiencies, partially offset by compensation investments of a couple hundred basis points. On Q4 burn rate, they said the percentage assumption for Q4 is about right and the working-days dynamic affects the comparison. They noted conversion rate progress and some period-to-period fluctuations in capacity days.
"In terms of the Q4 burn rate, yes, I think that's about right in terms of the percentage conversion assumption for Q4." — Jason Knoblauch (CFO)
Demand by customer type and phase
Q (Cassidy Epps · Jefferies): She asked for context on demand by customer cohort and by business segment, such as Phase I versus Phase II and FSP versus FSO. She wanted to know where demand is coming from.
A: They said the sector is in the middle of a market recovery and they are optimistic about the outlook. Biotech recovered faster and showed almost double-digit bookings growth in 2026, while biopharma recovery is following and RFPs from biopharma are increasing. They said both biotech and biopharma are now generating RFP and pipeline flow.
"I think we are starting to get into the middle of this market recovery." — Anshul Thakral (CEO)
Big pharma wallet share; Worldwide deal effects
Q (Jailendra Singh · Truist): He asked whether wallet share or sourcing behavior among large pharma customers is changing and whether scale matters. He also asked how the Worldwide deal changes the company approach to CPS work and how quickly it will show in bookings.
A: They said scale has always mattered and the top CROs with global footprints continue to be the viable players. On Worldwide, they said the deal adds capabilities sponsors asked for, notably an integrated bioanalytical lab and an expanded Texas network with a 300-bed CRU network for larger cohorts. They said the deal closed last week, they won their first bioanalytical lab award yesterday, and bookings conversion will come though they would not commit to a specific quarter.
"So this is really about adding capabilities, not just capacity." — Anshul Thakral (CEO)
Is Worldwide the last step?
Q (Kevin Caliendo · UBS): He asked whether the Worldwide acquisition is the last step toward the company’s strategic goals and what additional capabilities Fortrea still wants to add over the next few years.
A: They said this is the first step in a long journey to establish Fortrea as a CRO of choice for evidence generation. They want to support sponsors across the spectrum from first-in-human to post-approval and will keep filling capability gaps via organic investments and acquisitions. The company sees this as just the start of a multi-year effort.
"No, I'd say this is our first step, first step in a long journey, a long journey in establishing -- marching towards our goals, but establishing Fortrea as a CRO of choice when it comes to evidence generation." — Anshul Thakral (CEO)
Path to EBITDA for Worldwide; CPS sales cycle
Q (Justin Bowers · Deutsche Bank): He asked what actions will drive the acquired asset to be EBITDA profitable in 2027 and what initiatives will do that. He also asked about CPS sales cycle length and booking patterns versus peers.
A: They said the immediate focus is integrating the asset and embedding it into Fortrea's commercial pipeline to convert CPS opportunities into direct fee profit. They are repiping CPS opportunities into the P&L and working the sales funnel to fill it. They added CPS sales cycles tend to be shorter, with studies burning faster and decision times ranging from about 6 weeks to 5 or 6 months depending on client size and funding.
"Primary focus out of the gate has been on the commercial apparatus around it." — Jason Knoblauch (CFO)
Path to mid-teens margins and risks
Q (Charles Rhyee · TD Cowen): He asked whether reaching mid-teens EBITDA margins with the current structure is still reasonable and what could hamper that progress. He also asked about contract cancellations and amendments.
A: They said getting to mid-teens margins remains their true north and the strategy is growth plus margin expansion. They see a clear path but noted it requires consistent bookings and favorable market conditions; it's not easy and needs work quarter by quarter. On cancellations and amendments, they said the quarter was slightly elevated but within one standard deviation and that they grouped cancellations and negative amendments versus positive ones.
"I think as you said, getting back to what I would consider competitor level profitability margins defined as competitors of size, scale and breadth of services that we have, getting into that mid-teens margin remains our true north." — Anshul Thakral (CEO)
Book-to-bill growth and China business
Q (Albert Hu · Citi): He asked how the current book-to-bill ratio affects next-year growth and whether the Street’s low-single-digit growth assumptions are doable. He also asked about China business and any impact from the COINS Act proposal.
A: Management said they are not giving 2027 guidance now and are focused on solidifying Q4 contracts before commenting on next year. On China, they said service providers do not appear to be impacted and Fortrea is an at-scale player benefiting from multinationals running trials in China and Chinese biotech companies going global. They described China as a positive trend for pipeline, RFPs and bookings in 2026.
"From everything we can see, the concept of service providers is not impacted." — Anshul Thakral (CEO)
Headwinds/tailwinds for 2027
Q (Ann Hynes · Mizuho): She asked for any high-level headwinds or tailwinds to highlight for 2027 even though no guidance was given.
A: They reiterated they are not giving 2027 guidance at this time. They said sector recovery and consistent bookings, not just elevated bookings, will determine how 2027 plays out. Consistent quarter-over-quarter bookings are important for steady growth into next year.
"As Jason said, we're not giving 2027 guidance." — Anshul Thakral (CEO)
Tech versus people in service delivery
Q (Jared Haase · William Blair): He asked how much of the service delivery improvement is technology versus changes in team structure, oversight and training. He wanted to know the split between tech and people levers.
A: They said it's a bit of both, with the early focus more on restructuring and people. Over time it's shifting to a balance as technology (FIT) comes online and adds process improvements and efficiency. They said focusing on project delivery rather than task delivery improves economics, customer satisfaction and repeat business.
"It's about making sure we're really seen as a professional services organization, a professional services organization that is responsible for project delivery, not just task delivery." — Anshul Thakral (CEO)